Patents by Inventor Dongxu Shu

Dongxu Shu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240084304
    Abstract: Provided are a composition and method for inhibiting angiotensinogen (AGT) protein expression. Specifically, provided are a composition and method capable of being used for reducing AGT gene expression and treating AGT-related diseases and disorders. Provided are an AGT dsRNA reagent capable of being used for reducing AGT expression in a cell and an object, an AGT antisense polynucleotide reagent, a composition containing the AGT dsRNA reagent, and a composition containing the AGT antisense polynucleotide reagent.
    Type: Application
    Filed: September 25, 2023
    Publication date: March 14, 2024
    Applicant: Shanghai Argo Biopharmaceutical Co., Ltd.
    Inventors: Dongxu Shu, Pengcheng Patrick Shao
  • Publication number: 20240076270
    Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.
    Type: Application
    Filed: January 26, 2023
    Publication date: March 7, 2024
    Inventors: Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
  • Patent number: 11597701
    Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 7, 2023
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
  • Publication number: 20220204976
    Abstract: The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.
    Type: Application
    Filed: January 8, 2020
    Publication date: June 30, 2022
    Inventors: Zhen Li, Dongxu Shu, Anthony Nicholas, Rui Zhu, Jeffrey Carlson, So Wong, Xiaokai Li, Erich Altenhofer, Matthew Fowler-Watters, Bo Chen
  • Publication number: 20210093725
    Abstract: Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for ?v?3 integrin and/or ?v?5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin ?v?3, integrin ?v?5, or both integrin ?v?3 and integrin ?v?5. Compositions that include integrin targeting ligands and methods of use are also described.
    Type: Application
    Filed: April 26, 2019
    Publication date: April 1, 2021
    Inventors: Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
  • Publication number: 20210069337
    Abstract: Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for ?v?3 integrin and/or ?v?5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin ?v?3, integrin ?v?5, or both integrin ?v?3 and integrin ?v?5. Compositions that include integrin targeting ligands and methods of use are also described.
    Type: Application
    Filed: October 23, 2020
    Publication date: March 11, 2021
    Inventors: Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
  • Publication number: 20200369613
    Abstract: Synthetic av?6 integrin ligands of Formula I having serum stability and affinity for integrin av?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin av?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include avB6 integrin ligands and methods of use are also described.
    Type: Application
    Filed: October 31, 2018
    Publication date: November 26, 2020
    Inventors: Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
  • Patent number: 10730833
    Abstract: Described is a method to make diindolylmethanes and indolyl/pyrrolylmethanes, The method includes the steps of contacting an ether comprising an arylpropargyl moiety and an amine-protected, substituted or unsubstituted aniline moiety with a substituted or unsubstituted indol or a substituted or unsubstituted pyrrole, in the presence of a metal-containing catalyst, for a time and at a temperature to cause an annulation/arylation cascade reaction that yields a diindolylmethane or a indolyl/pyrrolylmethane. The resulting compounds are effective to modulate activity of arylhydrocarbon receptors, to inhibit activity of PCSK9, and to stimulate secretion of glucagon-like peptide 1 in mammals.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: August 4, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Weiping Tang, Xiaoxun Li, Dongxu Shu, Gabrielle N. Winston-McPherson
  • Publication number: 20180222861
    Abstract: Described is a method to make diindolylmethanes and indolyl/pyrrolylmethanes, The method includes the steps of contacting an ether comprising an arylpropargyl moiety and an amine-protected, substituted or unsubstituted aniline moiety with a substituted or unsubstituted indol or a substituted or unsubstituted pyrrole, in the presence of a metal-containing catalyst, for a time and at a temperature to cause an annulation/arylation cascade reaction that yields a diindolylmethane or a indolyl/pyrrolylmethane. The resulting compounds are effective to modulate activity of arylhydrocarbon receptors, to inhibit activity of PCSK9, and to stimulate secretion of glucagon-like peptide 1 in mammals.
    Type: Application
    Filed: April 5, 2018
    Publication date: August 9, 2018
    Inventors: Weiping Tang, Xiaoxun Li, Dongxu Shu, Gabrielle N. Winston-McPherson
  • Patent number: 9969686
    Abstract: Described is a method to make diindolylmethanes and indolyl/pyrrolylmethanes, The method includes the steps of contacting an ether comprising an arylpropargyl moiety and an amine-protected, substituted or unsubstituted aniline moiety with a substituted or unsubstituted indol or a substituted or unsubstituted pyrrole, in the presence of a metal-containing catalyst, for a time and at a temperature to cause an annulation/arylation cascade reaction that yields a diindolylmethane or a indolyl/pyrrolylmethane. The resulting compounds are effective to modulate activity of arylhydrocarbon receptors, to inhibit activity of PCSK9, and to stimulate secretion of glucagon-like peptide 1 in mammals.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 15, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Weiping Tang, Xiaoxun Li, Dongxu Shu, Gabrielle N. Winston-McPherson
  • Publication number: 20160039754
    Abstract: Described is a method to make diindolylmethanes and indolyl/pyrrolylmethanes, The method includes the steps of contacting an ether comprising an arylpropargyl moiety and an amine-protected, substituted or unsubstituted aniline moiety with a substituted or unsubstituted indol or a substituted or unsubstituted pyrrole, in the presence of a metal-containing catalyst, for a time and at a temperature to cause an annulation/arylation cascade reaction that yields a diindolylmethane or a indolyl/pyrrolylmethane. The resulting compounds are effective to modulate activity of arylhydrocarbon receptors, to inhibit activity of PCSK9, and to stimulate secretion of glucagon-like peptide 1 in mammals.
    Type: Application
    Filed: August 5, 2015
    Publication date: February 11, 2016
    Inventors: Weiping Tang, Xiaoxun LI, Dongxu Shu, Gabrielle N. Winston-McPherson